Abstract
In solid organ transplantation, the graft is generally inaccessible to localized pharmacologic therapy. Lung transplantation represents the exception, however, in that aerosolized pharmacologic agents have direct access to the donor graft, and the technology for delivering medication by the inhalational route is well developed for other pulmonary disorders. In 1988, a team of investigators at the University of Pittsburgh made the decision to pursue aerosolized immunosuppression for lung transplant recipients based upon the success of other experimental models of localized immunosuppression.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Griffith BP, Paradis IL, Zeevi A et al. Immunologically mediated disease of the airways after lung transplantation. Ann Surg 1988; 208: 371.
Yousem SA, Berry GJ, Brunt EM et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung rejection study group. J Heart Lung Transplant 1990; 9: 593.
Paradis I, Yousem S, Griffith BP. Airway obstruction and bronchiolitis obliterans after lung transplantation. Clin Chest Med 1993; 14: 751.
Cooper JD, Billingham M, Egan T et al. A working formulation for nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 1993; 12: 713.
Zenati M, Duncan AJ, Burckart GJ et al. Immunosuppression with aerosolized cyclosporin for prevention of lung rejection in a rat model. Eur J Cardiothorac Surg 1991; 5: 266.
Trulock EP. Management of lung transplant rejection. Chest 1993; 103: 1566.
Bando K, Paradis IL, Konishi H et al. Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management. J Thoracic Cardiovas Surg 1995; 110: 4.
Glanville GR, Baldwin JC, Burke CM et al. Obliterative bronchiolitis after heart-lung transplantation: apparent arrest by augmented immunosuppression. Ann Int Med 1987; 107: 300.
Theodure J, Starnes VA, Lewiston NJ. Obliterative bronchiolitis. Clin Chest Med 1990; 11: 309.
Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725.
Ascher NL, Chen S, Hoffman RA et al. Maturation of cytotoxic T cells within sponge matrix allografts. J Immunol 1983; 131: 617.
Wolf JS, McGavic JD, Hume DM. Inhibition of the effector mechanism of transplant immunity by local graft irradiation. Surg Gynecol Obstet 1969; 128: 584.
Gergely NF, Coles JC. Prolongation of heterotopic cardiac allografts in dogs by topical irradiation. Transplantation 1970; 9: 193.
Fidler JP, Alexander JW, Smith EJ et al. Radiation reversal of acute rejection in patients with life threatening infection. Arch Surg 1973; 107: 256.
Ruers TJM, Buurman WA, van der Linden CJ et al. Local inhibition of major histocompatibility complex class II induction within the graft: an effective way to induce immunosuppression. Transplant Proc 1987; 19: 246.
Ruers T, Daemen M, Thijssen H et al. Sensitivity of graft rejection in rats to local immunosuppressive therapy. Transplantation 1988; 46: 820.
Stepkowski SM, Goto S, Ito T et al. Prolongation of heterotopic heart allograft survival by local delivery of continuous low-dose cyclosporine therapy. Transplantation 1989; 47: 17.
Burckart GJ, Dowling R, Zenati M et al. Cyclosporine administration by aerosol. J Clin Pharmacol 1989; 29: 860.
Dowling RD, Zenati M, Burckart GJ et al. Aerosolized cyclosporine as single agent immunotherapy in canine lung allografts. Surgery 1990; 108: 198.
Keenan RJ, Duncan AJ, Yousem SA et al. Improved immunosuppression with aerosolized cyclosporine in experimental pulmonary transplantation. Transplantation 1992; 53: 20.
Muggenburg BA, Hoover MD, Griffith BP et al. Administration of cyclosporine by aerosol: A feasibility study in beagle dogs. J Aerosol Med 1990; 3: 1.
O’Riordan TG, Duncan SR, Burckart GJ et al. Production of an aerosol of cyclosporine as a prelude to clinical studies. J Aerosol Med 1992; 5: 171.
Iacono A, Keenan RJ, Duncan SR et al. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Resp Crit Care Med (in press).
O’Riordan TG, Iacono A, Keenan RJ et al. Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. Am J Resp Crit Care Med 1995; 151: 516.
Iacono A, Keenan R, Zeevi A et al. Improvement of acute allograft rejection refractory to conventional immunosuppressive therapy with aerosolized cyclosporine in lung transplant recipients. Am J Resp Crit Care Med 1995; 151: A85.
Akutsu I, Fukuda T, Majima K et al. Inhibitory effect of inhaled FK-506 on increased bronchial responsiveness and eosinophil infiltration in the airway mucosa. Arerugi 1992; 41: 543.
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Burckart, G.J., Keenan, R.J., Iacono, A.T., Griffith, B.P. (1996). Cyclosporine Aerosol in Lung Transplantation. In: Local Immunosuppression of Organ Transplants. Medical Intelligence Unit. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-22105-1_13
Download citation
DOI: https://doi.org/10.1007/978-3-662-22105-1_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-22107-5
Online ISBN: 978-3-662-22105-1
eBook Packages: Springer Book Archive